Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin versus metformin for oocyte and embryo outcomes in insulin-resistant women with polycystic ovary syndrome undergoing IVF
IRCT20220803055607N1Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in polycystic ovary syndrome (PCOS) comparing Sitagliptin with Metformin (2 arms). Primary endpoints: Oocyte and embryo quality, Number of retrieved oocytes and 2 more. Started Aug 2022; status: completed.
02
Drugs
sitagliptinmetformin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT20220803055607N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220803055607N1.